The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Merck & Co. announced that the U.S. Food and Drug Administration accepted for review supplemental New Drug Applications (sNDAs) for Pifeltro and Delstrigo.
Dr. Robert Redfield, the new head of the U.S. Centers for Disease Control and Prevention, boldly predicted in April 2018 that the AIDS epidemic can be defeated by 2025. Merck, Janssen and Gilead Sciences all released clinical data for HIV treatments that could make Redfield’s prediction a reality.
An experimental HIV immunotherapy treatment is showing significant promise in clinical testing. A study shows the two-drug combination is capable of suppressing HIV for months at a time.
AIDS researchers in Hong Kong say new research – tested on mice – indicates a functional cure for HIV, eventually leading to a new antibody that could be used for prevention and treatment.